Mint is reporting today that India will soon issue its compulsory licence for a cancer drug. A CL allows generic manufacturers to produce a medicine even if the discoverer of the product still has a valid patent. India issued its first patent (for Bayer’s Nexavar) last year. The Indian generic version of that drug is already available for mail order to the USA.
The new CL is for dasatinib (Sprycel), a medicine to treat chronic myeloid leukaemia that was developed by Bristol Myers Squibb. The new CL will be even more controversial because the patent belongs to a US company. American manufacturers thought that diplomatic pressure from the US administration might have limited these moves